Cambridge Healthtech Institute’s 3rd Annual

Multi-Cancer Early Detection

Evidence Generation and Market Access for MCED Tests

March 12-13, 2025

Multi-cancer early detection promises to improve cancer diagnosis, treatment, and patient care. However, introducing MCED technologies into clinical care requires evaluation and assessment of benefits and risks, potential outcomes, costs, and value. Cambridge Healthtech Institute’s 3rd Annual Multi-Cancer Early Detection meeting convenes key stakeholders to discuss how MCED will impact clinical care, outstanding challenges in evidence generation, test reimbursement, market adoption, equitable patient access, and impact on the big pharma oncology models.

Coverage will include, but is not limited to:

Multi-cancer early detection and population screening
Business model and market access for early cancer detection diagnostics
Impact of early detection technologies on big pharma models
Clinical validation of MCED liquid biopsy tests
Market access, regulatory, and reimbursement considerations for MCED
Molecular characterization for targeted therapy selection
Predictive and prognostic cancer biomarkers and companion diagnostics
Integrating genomic and molecular testing into patient care
Equitable patient access for early cancer detection
Evidence generation for MCED and clinical trials update

The deadline for priority consideration is August 16, 2024.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: